Alzamend neuro announces the initiation of a phase i/iia trial for its immunotherapy vaccine (alzn002) to treat mild to moderate dementia of the alzheimer's type

Atlanta--(business wire)---- $acad #alzn002--alzamend neuro announces initiation of phase i/iia trial for its immunotherapy vaccine alzn002 to treat mild to moderate dementia of alzheimer's type
ACAD Ratings Summary
ACAD Quant Ranking